PRODUCT INFORMATION
Empagliflozin
Item No. 17375
CAS Registry No.: 864070-44-0
Formal Name: (1S)-1,5-anhydro-1-C-[4-chloro-3- OH
[[4-[[(3S)-tetrahydro-3-furanyl]oxy]
phenyl]methyl]phenyl]-D-glucitol
OH
Synonym: BI 10773 O
MF: C23H27ClO7
FW: 450.9 O OH
Purity: ≥98%
OH
Stability: ≥2 years at -20°C
O Cl
Supplied as: A crystalline solid
UV/Vis.: λmax: 224 nm
Laboratory Procedures
For long term storage, we suggest that empagliflozin be stored as supplied at -20°C. It should be stable
for at least two years.
Empagliflozin is supplied as a crystalline solid. A stock solution may be made by dissolving the empagliflozin
in the solvent of choice. Empagliflozin is soluble in organic solvents such as ethanol, DMSO, and dimethyl
formamide, which should be purged with an inert gas. The solubility of empagliflozin in these solvents is
approximately 30 mg/ml.
Empagliflozin is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers,
empagliflozin should first be dissolved in ethanol and then diluted with the aqueous buffer of choice.
Empagliflozin has a solubility of approximately 0.5 mg/ml in a 1:1 solution of ethanol:PBS (pH 7.2) using this
method. We do not recommend storing the aqueous solution for more than one day.
Description
Inhibiting renal glucose reabsorption through the sodium-glucose cotransporter (SGLT) offers an
insulin-independent alternative to controlling blood glucose concentrations in patients with
type 2 diabetes.1,2 The majority of glucose is reabsorbed from glomerular filtrate by SGLT2, which is
predominantly expressed in the kidney S1 segment of the proximal tubule. Empagliflozin is a potent SGLT2
inhibitor (IC50 = 3.1 nM) that demonstrates a high degree of selectivity (>2,500-fold) over SGLT1, 4, 5,
and 6.3 In clinical trials of patients with type 2 diabetes, empagliflozin was shown to lower fasting and
postprandial glucose levels by increasing total glucose excretion, improving β-cell function, and shifting
substrate utilization from glucose to lipids.4
References
1. Tahrani, A.A. and Barnett, A.H. Dapagliflozin: A sodium glucose cotransporter 2 inhibitor in development
for type 2 diabetes. Diabetes Ther. 1(2), 45-56 (2010).
2. Komoroski, B., Vachharajani, N., Feng, Y., et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved
glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin. Pharmacol. Ther. 85(5),
513-519 (2009).
3. Grempler, R., Thomas, L., Eckhardt, M., et al. Empagliflozin, a novel selective sodium glucose
contransporter-2 (SGLT-2) inhibitor: Characterisation and comparison with other SGLT-2 inhibitors.
Diabetes Obes. Metab. 14, 83-90 (2012).
4. Ndefo, U.A., Anidiobi, N.O., Basheer, E., et al. Empagliflozin (Jardiance): A novel SGLT2 inhibitor for the
treatment of type-2 diabetes. P. T. 40(6), 364-368 (2015).
WARNING CAYMAN CHEMICAL
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE. 1180 EAST ELLSWORTH RD
SAFETY DATA ANN ARBOR, MI 48108 · USA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after
handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution. PHONE: [800] 364-9897
WARRANTY AND LIMITATION OF REMEDY [734] 971-3335
Buyer agrees to purchase the material subject to Cayman’s Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information
can be found on our website.
FAX: [734] 971-3640
[email protected] Copyright Cayman Chemical Company, 10/07/2015
WWW.CAYMANCHEM.COM
